Xtant Medical Holdings, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On August 10, 2026, Xtant Medical Holdings amended its term and revolving loan agreements with MidCap Financial Trust (Agent) and Apollo-affiliated lenders. The amendments modified amortization schedules (term loan principal payments: $309,973/month April–September 2026, $360,000/month October–December 2026, then $410,000/month from January 2027 onward) and reset minimum net revenue covenants through December 2028 (ranging $68.0M–$84.0M). The lender group includes Apollo Alster Lending Fund, MidCap Funding XIII Trust, and MidCap Funding IV Trust. No new debt amount is disclosed; the filing addresses covenant restructuring and payment schedule adjustment on existing facilities.
Why this rating
Routine covenant amendment and amortization adjustment; no new borrowing disclosed. Relative to $45M market cap, existing debt appears material but restructuring is operational maintenance, not business-changing. No deal, refinancing event, or strategic shift evident.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.